Survival Following Radiotherapy in Young Women with Localized Early-stage Breast Cancer According to Molecular Subtypes

Overview

Journal Cancer Med

Specialty Oncology

Date 2019 Apr 25

PMID 31016890

Citations 7

Authors

Qi-Qi Liu

He-Fen Sun

Xue-Li Yang

Meng-Ting Chen

Yang Liu

Yang Zhao

Yuan-Yuan Zhao

Wei Jin

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate the significance and benefit of radiotherapy (RT) in young early-stage breast cancer patients according to different molecular subtypes.

Methods: We conducted a retrospective cohort study utilizing the Surveillance, Epidemiology, and End Results database with known hormone receptor (HoR) and human epidermal growth factor receptor 2 (HER2) status. Female patients aged 18-45, received RT treatment, and diagnosed with stage T1-3, N0-3, M0 primary breast cancer between 2010 and 2013 were identified.

Results: Of all the 23 148 included patients, 14 708 (63.54%), 3385 (14.62%), 1225 (5.29%), and 3830 (16.55%) were diagnosed with luminal-A (HoR + HER2-), luminal-B (HoR + HER2+), HER2-enriched (HoR-HER2+), and triple-negative (HoR-HER2-) breast cancer, respectively. RT was significantly correlated with improved overall survival (OS, HR: 0.295; 95% CI:0.138-0.63, P = 0.002) and breast cancer-specific survival (BCSS, HR: 0.328; 95% CI: 0.153-0.702, P = 0.004) in HER2-enriched patients. In addition, a significantly prolonged OS was also observed when RT was given to luminal-A (HR: 0.696; 95% CI: 0.538-0.902, P = 0.006) and luminal-B (HR: 0.385; 95% CI:0.199-0.744, P = 0.005) breast cancer patients compared to those without RT. Multivariable-adjusted analyses showed that HER2 was a significant favorable factor for RT benefit in breast cancer patients.

Conclusions: RT could offer significant survival benefit in luminal-A, luminal-B, and especially HER2-enriched young early-stage breast cancer female patients. The results enabled clinicians to predict the benefits of RT and improve evidence-based treatment for breast cancer patients.

Citing Articles

ABO Blood Type and Pretreatment Systemic Inflammatory Response Index Associated with Lymph Node Metastasis in Patients with Breast Cancer.

Xiong N, Han W, Yu Z Int J Gen Med. 2024; 17:4823-4833.

PMID: 39465189 PMC: 11512788. DOI: 10.2147/IJGM.S486873.

Pretreatment System Inflammation Response Index (SIRI) is a Valuable Marker for Evaluating the Efficacy of Neoadjuvant Therapy in Breast Cancer Patients.

Zhang Y, Wu J, Chen W, Liang X Int J Gen Med. 2024; 17:4359-4368.

PMID: 39346633 PMC: 11439349. DOI: 10.2147/IJGM.S478000.

Association of molecular subtypes and treatment with survival in invasive micropapillary breast cancer: an analysis of the Surveillance, Epidemiology, and End Results database.

Tang Z, Li L, Huang X, Zhao Y, Huang L Breast Cancer. 2023; 31(2):205-216.

PMID: 38043116 DOI: 10.1007/s12282-023-01523-9.

Survival comparison between postoperative and preoperative radiotherapy for stage I-III non-inflammatory breast cancer.

Zhang Y, Xu Z, Chen H, Sun X, Zhang Z Sci Rep. 2022; 12(1):14288.

PMID: 35995985 PMC: 9395522. DOI: 10.1038/s41598-022-18251-3.

GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients.

Zeng J, Wu H, Liu D, Li L, Li J, Wang Q World J Surg Oncol. 2022; 20(1):212.

PMID: 35729577 PMC: 9214976. DOI: 10.1186/s12957-022-02679-y.

References

Kyndi M, Sorensen F, Knudsen H, Overgaard M, Nielsen H, Overgaard J . Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008; 26(9):1419-26. DOI: 10.1200/JCO.2007.14.5565. View

Bartelink H, Horiot J, Poortmans P, Struikmans H, Van den Bogaert W, Fourquet A . Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007; 25(22):3259-65. DOI: 10.1200/JCO.2007.11.4991. View

Liu Q, Sun H, Yang X, Chen M, Liu Y, Zhao Y . Survival following radiotherapy in young women with localized early-stage breast cancer according to molecular subtypes. Cancer Med. 2019; 8(6):2840-2857. PMC: 6558475. DOI: 10.1002/cam4.2186. View

Thewes B, Bell M, Butow P, Beith J, Boyle F, Friedlander M . Psychological morbidity and stress but not social factors influence level of fear of cancer recurrence in young women with early breast cancer: results of a cross-sectional study. Psychooncology. 2013; 22(12):2797-806. DOI: 10.1002/pon.3348. View

Shen X, Anne P, Keith S, Wojcieszynski A, Mishra M, Bar-Ad V . Radiation therapy use and outcomes among older women with ER-positive and ER-negative stage I breast cancer. Am J Clin Oncol. 2012; 37(3):241-7. DOI: 10.1097/COC.0b013e318271b326. View

Sperduto P, Kased N, Roberge D, Xu Z, Shanley R, Luo X . Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys. 2011; 82(5):2111-7. PMC: 3172400. DOI: 10.1016/j.ijrobp.2011.02.027. View

Chen L, Zhang J, Chen J, Liu L, Liang L, Shangguan Z . Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes. Oncotarget. 2017; 8(26):42917-42925. PMC: 5522115. DOI: 10.18632/oncotarget.17170. View

Tseng Y, Uno H, Hughes M, Niland J, Wong Y, Theriault R . Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. Int J Radiat Oncol Biol Phys. 2015; 93(3):622-30. DOI: 10.1016/j.ijrobp.2015.07.006. View

Abubakar M, Sung H, Bcr D, Guida J, Tang T, Pfeiffer R . Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population. Breast Cancer Res. 2018; 20(1):114. PMC: 6145192. DOI: 10.1186/s13058-018-1033-8. View

10.

Kim Y, Kim J, Kim I . Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database. J Cancer Res Clin Oncol. 2018; 144(9):1803-1816. DOI: 10.1007/s00432-018-2697-2. View

11.

Donnelly L, Watson M, Moynihan C, Bancroft E, Evans D, Eeles R . Reproductive decision-making in young female carriers of a BRCA mutation. Hum Reprod. 2013; 28(4):1006-12. DOI: 10.1093/humrep/des441. View

12.

Gnerlich J, Deshpande A, Jeffe D, Sweet A, White N, Margenthaler J . Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009; 208(3):341-7. PMC: 3262236. DOI: 10.1016/j.jamcollsurg.2008.12.001. View

13.

Jayasekera J, Schechter C, Sparano J, Jagsi R, White J, Chapman J . Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer. J Natl Cancer Inst. 2018; 110(12):1370-1379. PMC: 6292790. DOI: 10.1093/jnci/djy128. View

14.

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

15.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

16.

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

17.

Poortmans P . Evidence based radiation oncology: breast cancer. Radiother Oncol. 2007; 84(1):84-101. DOI: 10.1016/j.radonc.2007.06.002. View

18.

Cho W, Park W, Choi D, Kim Y, Kim J, Kim S . Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16). Clin Breast Cancer. 2018; 19(1):78-86. DOI: 10.1016/j.clbc.2018.08.009. View

19.

Bartelink H, Horiot J, Poortmans P, Struikmans H, Van Den Bogaert W, Barillot I . Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med. 2002; 345(19):1378-87. DOI: 10.1056/NEJMoa010874. View

20.

Halbert C, Kessler L, Mitchell E . Genetic testing for inherited breast cancer risk in African Americans. Cancer Invest. 2005; 23(4):285-95. DOI: 10.1081/cnv-58819. View